Can Vyvanse cause hair loss? This is a question increasingly raised by patients taking lisdexamfetamine — sold in the UK as Elvanse — for ADHD. Whilst hair loss is not listed as a recognised side effect in the UK Summary of Product Characteristics for Elvanse, some patients do report increased shedding. Understanding whether this is a direct drug effect, an indirect consequence of appetite suppression or sleep disruption, or an unrelated condition is essential before making any changes to your medication. This article explores the evidence, practical steps to take, and alternative ADHD treatments available in the UK.
Summary: Can Vyvanse cause hair loss? Hair loss is not a listed side effect of lisdexamfetamine (Elvanse) in the UK, but some patients report shedding that is likely multifactorial rather than a direct drug effect.
- Lisdexamfetamine (Elvanse) is the UK equivalent of Vyvanse, licensed by the MHRA for ADHD in adults and children aged six and over.
- Hair loss does not appear in the current UK Summary of Product Characteristics (SmPC) for Elvanse; no established causal link exists.
- Appetite suppression — a common Elvanse side effect — can cause nutritional deficiencies, particularly iron and protein deficiency, which are well-evidenced contributors to hair shedding.
- Telogen effluvium, a temporary diffuse shedding triggered by physiological stress, nutritional deficit, or sleep disruption, is the most plausible mechanism in lisdexamfetamine users.
- Atomoxetine (Strattera), a non-stimulant ADHD alternative, lists alopecia as an uncommon side effect in its UK SmPC, so switching may not resolve the concern.
- Suspected adverse drug reactions including hair loss should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Does Lisdexamfetamine (Elvanse) Cause Hair Loss?
Hair loss is not listed in the UK SmPC for Elvanse, and no established causal link exists; shedding in some users is more likely due to nutritional deficiencies, sleep disruption, or telogen effluvium than a direct drug effect.
Not sure if this is normal? Chat with one of our pharmacists →
Lisdexamfetamine dimesylate is a central nervous system stimulant licensed in the UK under the brand name Elvanse (note: Vyvanse is the equivalent US brand). In the UK, lisdexamfetamine is licensed by the MHRA for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and in children aged six years and over. It is not licensed in the UK for binge eating disorder (that indication exists in the USA only). Lisdexamfetamine is a prodrug that is converted in the body to dexamfetamine, which increases the availability of dopamine and noradrenaline in the brain, improving focus, impulse control, and executive function.
Hair loss is not listed as a recognised side effect in the current UK Summary of Product Characteristics (SmPC) for Elvanse, as published on the Electronic Medicines Compendium (EMC). However, a small number of patients and clinicians have reported hair shedding in association with lisdexamfetamine use, and similar stimulant medications have occasionally been linked to this concern in post-marketing surveillance data.
It is important to note that there is no established causal link between lisdexamfetamine and hair loss based on current clinical evidence. Hair shedding in people taking Elvanse may be attributable to other factors, including:
-
Nutritional deficiencies resulting from appetite suppression (a well-documented side effect)
-
Stress and sleep disruption, both of which can accompany ADHD and its treatment
-
Underlying conditions such as thyroid dysfunction or iron deficiency anaemia
-
Telogen effluvium, a temporary shedding response triggered by physiological or psychological stress
If you are concerned about hair loss whilst taking lisdexamfetamine, it is advisable to speak with your prescribing clinician before making any changes to your medication. Self-discontinuing a prescribed stimulant can have significant consequences for ADHD symptom management and overall wellbeing.
Have questions about your medication? Our pharmacists are here to help →
| Side Effect / Factor | Likelihood of Causing Hair Loss | Mechanism | Recommended Action |
|---|---|---|---|
| Lisdexamfetamine (Elvanse) direct effect | Not established; not listed in UK SmPC | No confirmed pharmacological mechanism; correlation only via Yellow Card reports | Do not self-discontinue; consult prescribing clinician |
| Nutritional deficiency (iron, protein) | Common indirect risk via appetite suppression | Reduced caloric and micronutrient intake impairs follicle cycling | Check serum ferritin; ensure adequate protein and iron-rich foods |
| Telogen effluvium | Plausible; triggered by physiological or psychological stress | Excess follicles shift to telogen (resting) phase; shedding 2–3 months after trigger | Identify and address underlying trigger; usually self-resolving |
| Sleep disruption / insomnia | Possible indirect contributor | Chronic poor sleep elevates cortisol, disrupting hair follicle cycling | Optimise sleep hygiene; review medication timing with clinician |
| Thyroid dysfunction or anaemia | Common independent cause; must be excluded | Hypothyroidism and iron-deficiency anaemia both cause diffuse hair thinning | Request FBC, serum ferritin, and TSH via GP |
| Atomoxetine (Strattera) — alternative ADHD treatment | Alopecia listed as uncommon in UK SmPC | Selective noradrenaline reuptake inhibition; mechanism for hair loss unclear | Not recommended as a switch for patients specifically concerned about hair loss |
| Guanfacine (Intuniv) — alternative ADHD treatment | Hair loss not a recognised concern per UK SmPC | Alpha-2A adrenergic receptor agonist; different side effect profile | Discuss suitability with prescriber; licensed for children and adolescents only |
How Common Is Hair Loss With ADHD Stimulant Medications?
Hair loss is considered an uncommon to rare reported event across ADHD stimulants and does not feature in NICE guidance (NG87); atomoxetine is the only UK-licensed ADHD medication that formally lists alopecia as an uncommon side effect.
Across the broader class of ADHD stimulant medications — including methylphenidate (e.g., Ritalin, Concerta XL) and amphetamine-based treatments such as lisdexamfetamine — hair loss is considered an uncommon to rare reported event. It does not feature prominently in large-scale clinical trials or in NICE guidance on ADHD pharmacotherapy (NG87).
Spontaneous reports submitted to pharmacovigilance databases, including the MHRA's Yellow Card scheme, have occasionally included hair thinning or shedding as a patient-reported concern with stimulant medications. These reports are valuable for signal detection but do not confirm causality — they reflect correlation rather than a proven drug-induced mechanism.
Among non-stimulant ADHD medications, atomoxetine (Strattera) — a selective noradrenaline reuptake inhibitor — lists alopecia as an uncommon side effect in its UK SmPC. This distinction is worth noting when comparing treatment options.
The overall prevalence of hair loss specifically attributable to lisdexamfetamine in the UK population is not well quantified, partly because:
-
Hair loss has multiple potential causes that are difficult to disentangle
-
Patients may not report it to their prescriber
-
It may resolve spontaneously without any medication change
Patients, carers, and healthcare professionals are all encouraged to report any suspected adverse drug reactions — including hair loss — via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). Reports from patients and carers are equally welcome and help build a more complete picture of real-world medication safety.
Why Some Medications Can Trigger Hair Shedding
Stimulants like lisdexamfetamine can indirectly trigger telogen effluvium through appetite suppression causing nutritional deficiencies, sleep disruption elevating cortisol, and psychological stress — rather than a direct pharmacological effect on hair follicles.
To understand why medications might contribute to hair loss, it helps to consider the normal hair growth cycle. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Disruption to this cycle — whether from illness, nutritional deficiency, hormonal change, or certain drugs — can push a disproportionate number of follicles into the telogen phase simultaneously, resulting in diffuse shedding known as telogen effluvium. Shedding typically becomes noticeable two to three months after the triggering event and usually improves once the underlying cause is addressed.
Stimulant medications like lisdexamfetamine can indirectly contribute to this process through several mechanisms:
-
Appetite suppression: Elvanse commonly reduces appetite, which may lead to reduced caloric intake and nutritional deficiencies. Iron deficiency and inadequate protein intake are the best-evidenced nutritional contributors to hair thinning. Zinc deficiency is a less common cause in the UK, and biotin deficiency is rare outside specific clinical contexts (such as certain gastrointestinal conditions or prolonged parenteral nutrition); routine supplementation with these micronutrients is not recommended without clinical evidence of deficiency.
-
Sympathetic nervous system activation: Stimulants increase noradrenaline activity, which may theoretically affect peripheral blood flow and follicular perfusion — however, direct evidence for this mechanism in humans remains limited and this remains a hypothesis rather than an established finding.
-
Sleep disruption: Insomnia is a recognised side effect of lisdexamfetamine, and chronic poor sleep is associated with elevated cortisol levels, which may negatively affect hair follicle cycling.
-
Psychological stress: Managing ADHD itself, or adjusting to a new medication regimen, can be a source of stress that independently triggers telogen effluvium.
It is therefore plausible that hair shedding observed in some lisdexamfetamine users is multifactorial rather than a direct pharmacological effect of the drug itself. Addressing nutritional intake and sleep hygiene may be as important as reviewing the medication.
What to Do If You Notice Hair Loss While Taking Lisdexamfetamine
Speak with your GP or prescribing specialist before stopping lisdexamfetamine; initial investigations should include FBC, serum ferritin, and TSH to identify common treatable causes of hair loss.
If you notice increased hair shedding after starting or adjusting your dose of lisdexamfetamine, the first and most important step is to speak with your GP or prescribing specialist rather than stopping the medication abruptly. Sudden discontinuation of a stimulant can lead to a rebound in ADHD symptoms and should only be done under medical supervision.
Your clinician will take a history and examine the pattern of hair loss to guide further investigation. In UK primary care, initial investigations typically include:
-
Full blood count (FBC) — to check for anaemia
-
Serum ferritin — iron deficiency is a common and treatable cause of hair loss
-
Thyroid stimulating hormone (TSH) — hypothyroidism frequently causes diffuse hair thinning
-
Vitamin B12 and folate — if dietary intake or absorption is a concern
-
Additional tests (such as vitamin D, zinc, liver function, renal function, or hormonal profile) should be guided by the clinical history and examination findings, rather than ordered routinely
Red flags that warrant prompt or early referral to a dermatologist include:
-
Patchy or inflammatory hair loss (which may suggest alopecia areata or tinea capitis)
-
Scarring alopecia (permanent follicular damage)
-
Rapid or progressive hair loss
-
Systemic symptoms suggesting an underlying condition
-
Signs of hyperandrogenism in women (e.g., irregular menstrual cycles, hirsutism, acne)
-
Diagnostic uncertainty or failure to respond to initial management
Practical steps you can take in the meantime include:
-
Ensuring adequate nutritional intake, particularly protein and iron-rich foods, even if appetite is reduced
-
Discussing meal timing strategies with your clinician to maximise nutrition around periods of lower appetite suppression
-
Maintaining good sleep hygiene and stress management practices
-
Avoiding harsh hair treatments, tight hairstyles, or excessive heat styling that may worsen shedding
If investigations reveal a nutritional deficiency or another treatable cause, addressing that directly may resolve the hair loss without any need to change your ADHD medication. Telogen effluvium typically improves within several months once the underlying trigger is managed. A referral to a dermatologist is appropriate if hair loss is significant, progressive, scarring, or does not improve with initial management.
Alternative ADHD Treatments and Their Side Effect Profiles
Methylphenidate-based medications and guanfacine are UK-licensed ADHD alternatives; guanfacine does not list hair loss as a concern, whereas atomoxetine lists alopecia as uncommon, making it a less suitable switch for patients specifically worried about hair shedding.
For patients who remain concerned about a possible link between lisdexamfetamine and hair loss, or who experience other intolerable side effects, there are several alternative ADHD treatments available in the UK. NICE guidance (NG87) recommends a shared decision-making approach when selecting pharmacotherapy, taking into account individual patient factors, comorbidities, and tolerability.
Methylphenidate-based medications (e.g., Ritalin, Concerta XL, Equasym XL) are a first-line stimulant option for both children and adults in the UK, alongside lisdexamfetamine. They work by blocking the reuptake of dopamine and noradrenaline. It should be noted that alopecia is listed in some UK SmPCs for methylphenidate products, typically at a frequency of 'not known'. The same indirect mechanisms seen with lisdexamfetamine — appetite suppression and sleep disruption — also apply. Other common side effects include headache and reduced appetite.
Atomoxetine (Strattera) is a non-stimulant option that selectively inhibits noradrenaline reuptake. Its UK SmPC lists alopecia as an uncommon side effect. It may therefore not be the most appropriate switch for patients specifically concerned about hair loss, and this should be discussed with the prescriber.
Guanfacine (Intuniv) is a non-stimulant licensed for children and adolescents in the UK. It acts on alpha-2A adrenergic receptors and has a different side effect profile, primarily causing sedation, fatigue, and blood pressure changes. Hair loss is not a recognised concern with this agent based on its current UK SmPC.
Ultimately, the decision to switch or adjust ADHD medication should be made collaboratively with a qualified prescriber. No medication is entirely free of side effects, and the benefits of well-managed ADHD — in terms of quality of life, relationships, and occupational functioning — must always be weighed carefully against tolerability concerns.
Useful UK resources:
-
EMC SmPC: Elvanse (lisdexamfetamine) — electronic-medicines-compendium.com
-
NICE NG87: ADHD diagnosis and management — nice.org.uk
-
MHRA Yellow Card scheme (report suspected side effects) — yellowcard.mhra.gov.uk
-
NHS: Hair loss (alopecia) — nhs.uk
-
British Association of Dermatologists (BAD) patient information: Telogen effluvium — bad.org.uk
-
Primary Care Dermatology Society (PCDS): Hair loss guidance — pcds.org.uk
Frequently Asked Questions
Can Vyvanse cause hair loss, and is it permanent?
Vyvanse (sold in the UK as Elvanse) is not officially linked to hair loss in its UK prescribing information, and any shedding associated with its use is most likely temporary rather than permanent. The most probable mechanism is telogen effluvium — a reversible, diffuse shedding triggered by nutritional deficiency, sleep disruption, or stress — which typically improves within several months once the underlying cause is addressed.
Could my Elvanse be causing my hair to thin because I'm not eating enough?
Yes, this is a plausible and important connection — appetite suppression is a well-documented side effect of lisdexamfetamine (Elvanse), and reduced food intake can lead to iron and protein deficiencies, both of which are established causes of hair thinning. Discussing meal timing strategies with your prescriber and ensuring adequate nutrition, particularly around periods of lower appetite, may help address the shedding without changing your ADHD medication.
Should I stop taking lisdexamfetamine if I notice hair shedding?
No — you should not stop lisdexamfetamine abruptly without speaking to your GP or prescribing specialist first, as sudden discontinuation can cause a significant rebound in ADHD symptoms. Your clinician can arrange blood tests to identify treatable causes such as iron deficiency or thyroid dysfunction, which may resolve the hair loss without any need to change your medication.
Does methylphenidate (Ritalin) cause hair loss too, or is it just lisdexamfetamine?
Alopecia is listed in some UK SmPCs for methylphenidate products (such as Ritalin and Concerta XL), typically at a frequency of 'not known', so it is not unique to lisdexamfetamine. Both medications share indirect mechanisms — appetite suppression and sleep disruption — that can contribute to hair shedding, meaning switching between stimulants may not necessarily resolve the issue.
What blood tests should my GP do if I'm losing hair on ADHD medication?
Your GP should initially check a full blood count (FBC), serum ferritin, and thyroid stimulating hormone (TSH), as anaemia, iron deficiency, and hypothyroidism are common and treatable causes of diffuse hair loss. Vitamin B12 and folate levels may also be checked if dietary intake or absorption is a concern, with further tests guided by your individual clinical history rather than ordered routinely.
How do I report a suspected side effect like hair loss from my ADHD medication in the UK?
You can report any suspected side effect — including hair loss — directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; reports from patients and carers are actively encouraged and do not require a healthcare professional to submit. These reports help build a more complete picture of real-world medication safety and can contribute to future updates in prescribing guidance.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
